Generex Biotechnology extends scope of U.S. patent protection for vaccine technology

15-Feb-2007

Generex Biotechnology Corporation announced that that its wholly owned subsidiary, Antigen Express, Inc., has received a Notice of Allowance in connection with US Patent Application No. 10/197,000 entitled Hybrid peptides Modulate the Immune Response. The specific award covers fundamental aspects of the design and use of Ii-Key antigenic epitope hybrids in treating disease.

According to the company, potentiation of the therapeutic and prophylactic potency of vaccines using Ii-Key hybrids is a core component of Antigen Express technology. Ii-Key is a small fragment of the MHC class II associated invariant chain (Ii protein) that works by increasing the ability of specific antigens to stimulate T helper cells. Antigen Express has recently initiated a Phase II clinical trial designed to test the efficacy of one of its immunotherapeutic Ii-Key hybrid vaccines (AE37) in breast cancer. It has also initiated clinical trials on a synthetic avian influenza vaccine designed using the same principal.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Peregrine Enters Contract Negotiations With U.S. DTRA for Hemorrhagic Fevers - U.S. Department of Defense Agency Has Selected Peregrine for a Multi-Year Award That Could Total $44.5 Million Pending Successful Contract Negotiations

Food safety in Europe - who is responsible for what? - BfR publishes 2. completely revised edition of the EU Food Safety Almanac

SemBioSys signs contract manufacturing agreement for plant-produced insulin with Cangene

Cellzome Achieves Clinical Candidate Milestone from Inflammation Alliance with GlaxoSmithKline

Bionomics BNC105 cancer clinical trials reach key milestones - Clinical program to be expanded

Crucell to sell Rhein Biotech GmbH to Dynavax

Active Biotech's nomination committee proposes election of an additional new board member

ITI Life Sciences licenses technology to Cognia to develop a database product to enhance drug discovery and development

Delisting of Merck Serono shares expected on July 18, 2007 - Squeeze Out Successfully Completed

Biotec Pharmacon's SBG shows promising effect in animal model for inflammatory bowel disease

MediGene Acquires Patents on Anti-Cancer Drugs Under Development - License agreements with the University of Chicago guarantee exclusive worldwide rights to the most important groups of patents in the field of oncolytic Herpes Simplex Viruses (HSV)

Novartis-Partner Antisoma stops ASA404 ovarian cancer trial